Latest Conference Articles

March 14th 2015, 8:21am

Interdisciplinary Prostate Cancer Congress

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.

March 4th 2015, 6:36am

Genitourinary Cancers Symposium (ASCO GU)

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

March 3rd 2015, 2:03pm

PER® Miami Breast Cancer Conference

The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who shared his view in a session at the 32nd Annual Miami Breast Cancer Conference.

March 3rd 2015, 9:40am

PER® Miami Breast Cancer Conference

Deanna J. Attai, MD, FACS, who interacts with her thousands of followers on Twitter, Facebook, YouTube, her blog, and other social media platforms, recently educated other physicians on what their role can be on social media.

March 2nd 2015, 3:53pm

Genitourinary Cancers Symposium (ASCO GU)

Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).

March 2nd 2015, 3:39pm

Genitourinary Cancers Symposium (ASCO GU)

Mohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.

March 2nd 2015, 12:10pm

PER® Miami Breast Cancer Conference

A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype and a retrospective analysis about the impact of radiation after breast conserving surgery took home top honors at the Miami Breast Cancer Conference this year.

March 2nd 2015, 10:48am

Genitourinary Cancers Symposium (ASCO GU)

A fourth of patients with sarcomatoid or poor-risk metastatic renal-cell carcinoma responded to treatment with the combination of sunitinib and gemcitabine.

March 2nd 2015, 9:50am

PER® Miami Breast Cancer Conference

Compelling clinical trial evidence supports the use of hypofractionated radiation as the standard of care for postmenopausal women with luminal A tumors and node-negative disease.

March 2nd 2015, 8:27am

Genitourinary Cancers Symposium (ASCO GU)

An investigational antibody that targets programmed death-ligand 1 (PD-L1) in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with metastatic renal cell carcinoma (mRCC) in an open-label phase Ib study.

February 28th 2015, 5:37pm

PER® Miami Breast Cancer Conference

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

February 28th 2015, 5:11pm

PER® Miami Breast Cancer Conference

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses optimizing adjuvant treatment in older patients with breast cancer.

February 28th 2015, 4:05pm

PER® Miami Breast Cancer Conference

Joan Lunden presented the keynote address at the Miami Breast Cancer Conference where she spoke powerfully and from the heart in a talk perfectly aligned with the meeting's focus on the patient perspective.

February 28th 2015, 3:03pm

PER® Miami Breast Cancer Conference

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

February 28th 2015, 2:40pm

PER® Miami Breast Cancer Conference

In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.

February 28th 2015, 11:55am

PER® Miami Breast Cancer Conference

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

February 28th 2015, 11:49am

Genitourinary Cancers Symposium (ASCO GU)

Ramucirumab added to docetaxel significantly improved PFS compared with docetaxel monotherapy as second-line treatment in a phase II study of patients with metastatic transitional cell carcinoma.

February 28th 2015, 9:22am

PER® Miami Breast Cancer Conference

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

February 28th 2015, 7:45am

Genitourinary Cancers Symposium (ASCO GU)

In patients evaluable for treatment response, the ORR with the combination was 50%, with 11% having a CR.

February 27th 2015, 5:45pm

Genitourinary Cancers Symposium (ASCO GU)

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.